Prognosis of patients with hepatocellular carcinoma and portal vein tumor thrombus treated with combination of transarterial chemoembolization and palliative thermal ablation. (31st December 2022)

• Record Type: Journal Article
• Authors: Zhou, Qunfang; An, Yongcheng; Liu, Ting; Liu, Zishan; Li, Ruixia; Wang, Chenmeng; Zhou, Feng; Liu, Congjuan; Zhu, Kangshun
• Is Part Of: International journal of hyperthermia. Volume 39:Number 1(2022)
• Page Start: 97
• Page End: 107
• Publication Date: 2022-12-31
• Subjects: Hepatocellular carcinoma -- portal vein tumor thrombus -- transarterial chemoembolization -- palliative -- thermal ablation; Thermotherapy -- Periodicals; 615.832
• DOI: 10.1080/02656736.2021.2021303
• Languages: English
• ISSNs: 0265-6736

Abstract

Abstract: Purpose: Transarterial chemoembolization (TACE) was obtained acceptable benefit for advanced hepatocellular carcinoma (HCC). Here in this study, we compared the benefit of TACE combined palliative thermal ablation with TACE alone for HCC with portal vein tumor thrombus (PVTT). Methods: Patients with HCC and PVTT were retrospectively analyzed from January 2012 to December 2017, who accepted treatment of TACE alone (TACE group) or TACE plus palliative thermal ablation (TACE + P-ablation group). Propensity score matching (PSM) was applied to balance differences between the two groups. Overall survival (OS) and progression-free survival (PFS) rates were compared between groups. Results: Median follow-up time was 7.4 (3.0–60.0) months. In the cohort, 142 patients were enrolled in TACE group and 86 patients were enrolled in TACE + P-ablation group. The pre-PSM estimated 6-, 12-, and 18-month OS rates for the TACE + P-ablation group were 70.9, 46.5, and 31%, respectively, whereas rates for the TACE group were 57, 23.1, and 10%, respectively. After PSM, OS and PFS rates remained coincident with the pre-PSM. Risk factors for poor OS included PVTT type III and type II relative to type I (HR = 1.76; 95% CI, 1.13–2.74; p = .01) and (HR = 1.86; 95% CI, 1.2–2.88; p = .006), TACE alone (HR = 1.40; 95% CI, 1.01–1.96; p = .04), a single TACE treatment (HR = 2.69; 95% CI, 1.79–4.03; p < .001), 2 or 3 TACE treatments (HR = 2.02; 95% CI, 1.32–3.09; p = .001). Conclusions: The combination of TACE and palliative thermal ablation for HCC with PVTT could obtain delayed progression and longer survival.